Neos Therapeutics (NEOS) has a profit margin of -38.35%, below the Healthcare sector average of 14.34%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2020
Trailing 12 months ending Sep 2020
As of the most recent data (September 2020), NEOS shows a profit margin of -38.35%. That compares with -35.99% in the prior-year period — down 6.6% year over year. That is below the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NEOS's profit margin is now -38.35% (was -35.99%) — a 6.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Neos Therapeutics is outperforming or lagging.
The Healthcare sector average profit margin is about 14.34%. Neos Therapeutics is at -38.35%, which is lower that average. That is roughly 367.3% below the sector mean. Use the comparison chart on this page to see how NEOS stacks up against individual peers as well.
That compares with -35.99% in the prior-year period — down 6.6% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Neos Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Neos Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -38.35%) with ownership activity and broader fundamentals.